This next-generation synthetic medicine active pharmaceutical ingredient (API) facility, will produce small molecule synthetic and peptide medicines including Lilly's oral GLP-1, orforglipron and expand Lilly's capacity to produce medicines and strengthen the company's global supply chain.
With each step toward a healthier world, we're motivated by one thing: making life better for millions more people.
